AC Immune SA (ACIU) stock

ACIUNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 13, 2026Score 3/30

$2.13−0.01 (-0.47%)

Close on Nov 13, 2026Market cap $216.71MP/E –Yield –

AC Immune EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

AC Immune's EV/EBITDA was 7.4× on Feb 26, 2021, against 22.6× a year earlier.

Period	Period end	Value	Change (pts)
2021	Feb 26, 2021	7.4×	+4.5
2020	Dec 31, 2020	3.0×	−19.7
2017	Feb 28, 2017	22.6×	−5.8
2016	Dec 30, 2016	28.5×	–

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ACIU.

Revenue growth-86.9% · median -59.3%

Operating margin-1940.1% · median -1414.0%

Advertisement
300 × 250

See a number that looks wrong?